Skip to main content
Equibles

James T. Hippel

CFO

BIO-TECHNE Corp (TECH)

Equibles does not estimate personal net worth.

Get an email with a short summary when BIO-TECHNE Corp publishes a filing, an earnings call transcript or a press release.

Get TECH alerts

About James T. Hippel

James T. Hippel is recorded as CFO at BIO-TECHNE Corp (TECH). The newest filing on record that lists James T. Hippel as CFO at BIO-TECHNE Corp (TECH) is dated September 14, 2021. The proxy statement of BIO-TECHNE Corp reports total compensation of $7,027,382 for James T. Hippel in fiscal 2025, including a base salary of $723,000. Disclosed compensation is on record for 8 fiscal years. James T. Hippel has spoken on 6 earnings calls and 1 other investor event across 1 company, most recently for BIO-TECHNE Corp on May 12, 2026. BIO-TECHNE Corp is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at BIO-TECHNE Corp includes Charles Kummeth (CEO), Kim Kelderman (COO and Board Member), Shane Bohnen (General Counsel) and 7 others.

James T. Hippel on recent calls

“So as we think about Q4, the guidance we gave on the earnings call was essentially a flat quarter year over year, which again, taking the 150 basis point headwind in an account for these two fast-track customers implies an underlying growth or a jump-off point for fiscal year 27 of a positive 2% or so, which is very…”
CFO, Bank of America Securities 2026 Global Healthcare Conference ·
“I'll begin with additional details on our Q3 financial performance, followed by thoughts on our forward outlook. Adjusted EPS for the quarter was $0.53, down $0.03 from the prior year, with foreign exchange having a favorable $0.02 impact.”
CFO, BIO-TECHNE Corp Q3 FY2026 Earnings Call ·
“I'll begin with additional details on our Q2 financial performance, followed by thoughts on our forward outlook. Adjusted EPS for the quarter was $0.46, up 10% year-over-year, with foreign exchange having a favorable impact of $0.04.”
CFO, BIO-TECHNE Corp Q2 FY2026 Earnings Call ·
“I'll begin with additional detail on our Q1 financial performance, followed by thoughts on our forward outlook. Adjusted EPS for the quarter was $0.42, flat year-over-year with foreign exchange having an immaterial impact.”
CFO, BIO-TECHNE Corp Q1 FY2026 Earnings Call ·
“I'll start with some additional details on our Q4 financial performance and then give some thoughts on the forward outlook. Starting with the overall fourth quarter financial performance.”
CFO, BIO-TECHNE Corp Q4 FY2025 Earnings Call ·

Affiliation history

Company network

Leadership on record at BIO-TECHNE Corp

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 BIO-TECHNE Corp (TECH) $723,000 $7,027,382
2024 BIO-TECHNE Corp (TECH) $695,167 $5,202,632
2023 BIO-TECHNE Corp (TECH) $668,430 $3,441,870
2022 BIO-TECHNE Corp (TECH) $636,600 $4,436,029
2021 BIO-TECHNE Corp (TECH) $600,500 $3,157,058
2020 BIO-TECHNE Corp (TECH) $566,000 $3,157,058
2019 BIO-TECHNE Corp (TECH) $514,188 $2,757,790
2018 BIO-TECHNE Corp (TECH) $476,100 $2,448,887

Recent activity